



# MITOCHONDRION

Official Journal of the [Mitochondria Research Society](#)

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Audience</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.2</b>
●	<b>Abstracting and Indexing</b>	<b>p.2</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.4</b>



ISSN: 1567-7249

### DESCRIPTION

**Mitochondrion** is a definitive, high profile, peer-reviewed international research journal. The scope of *Mitochondrion* is broad, reporting on basic science of mitochondria from all organisms and from basic research to pathology and clinical aspects of mitochondrial diseases. The journal welcomes original contributions from investigators working in diverse sub-disciplines such as evolution, biophysics, biochemistry, molecular and cell biology, genetics, pharmacology, toxicology, forensic science, programmed cell death, aging, cancer and clinical features of mitochondrial diseases.

**Mitochondrion** includes:

**MitoMatters:** Editorial and news of general interest invited by Editorial Office.

**Profiles and Perspectives:** Invited by Editorial Office and written by senior investigators in the field.

**The Mito Mew:** Editorial and news of general interest.

**Review Articles:** Reviews of major importance in mitochondrial biology. These articles will be peer-reviewed. Articles may be of any length; however, unusually long articles should be discussed with the editor before submission.

**Fast Track Articles:** Peer-reviewed, short studies that are refereed rapidly and published generally within 10 weeks. These papers should be a concise complete piece of work of special significance and timeliness and should not exceed 4 printed pages (i.e., 10 pages of double-spaced typescript, including tables and figures up to a total number of 4).

**Original Articles:** Peer-reviewed, high-quality, concise research investigations that represent new and significant contributions to science.

**Letters to the Editor:** Comments on papers published in the Journal and on other matters of interest to mitochondria researcher.

**Book Reviews:** invited by the editorial office.

**Announcements and Calendar:** Providing notices of forthcoming meetings, courses, and other events relevant to mitochondria researchers.

### AUDIENCE

Investigators working in diverse sub-disciplines such as evolution, biophysics, biochemistry, molecular and cell biology, genetics, pharmacology, toxicology, forensic science, programmed cell death, aging, cancer and clinical features of mitochondrial diseases.

## IMPACT FACTOR

---

2016: 3.704 © Thomson Reuters Journal Citation Reports 2017

## ABSTRACTING AND INDEXING

---

BIOBASE  
CAS  
Current Contents/Clinical Medicine  
MEDLINE®  
EMBASE  
Research Alert  
Science Citation Index Expanded  
EMBiology

## EDITORIAL BOARD

---

### *Editor-in-Chief:*

**Keshav K. Singh**, Joy and Bill Harbert Endowed Chair and Professor of Genetics and Pathology  
Department of Genetics, School of Medicine  
University of Alabama at Birmingham  
Kaul Genetics Building, Suite 620  
720 20th St. South  
Birmingham, AL 35294  
USA

Phone: +1 205-934-2750

Fax: +1 205-934-2766

### *Honorary Editor:*

**Anthony W. Linnane**, Epworth Medical Centre, Richmond (Melbourne), Victoria, Australia

### *Editorial Board Members:*

**Susanne Arnold**, Radboudumc, Nijmegen, Netherlands  
**Narayan Avadhani**, University of Pennsylvania, Philadelphia, Pennsylvania, USA  
**Yidong Bai**, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA  
**Vilhelm Bohr**, National Institute of Aging (NIA), Baltimore, Maryland, USA  
**Richard Boles**, Children's Hospital Los Angeles, Los Angeles, California, USA  
**Paul Brookes**, University of Rochester Medical Center, Rochester, New York, USA  
**Craig Cameron**, Pennsylvania State University, University Park, Pennsylvania, USA  
**Maria Louisa Campo**, University of Extremadura, Cáceres, Spain  
**Xin Jie Chen**, State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA  
**Patrick F. Chinnery**, Newcastle University, Newcastle upon Tyne, UK  
**Bruce H. Cohen**, Akron Children's Hospital, Akron, Ohio, USA  
**William C. Copeland**, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina, USA  
**Salvatore DiMauro**, Columbia University, New York, New York, USA  
**Francoise Foury**, Université Catholique de Louvain, Louvain-la-Neuve, Belgium  
**Erich Gnaiger**, Medizinische Universität Innsbruck, Innsbruck, Austria  
**Yu-ichi Goto**, National Center of Neurology & Psychiatry (NCNP), Tokyo, Japan  
**Lawrence I. Grossman**, Wayne State University School of Medicine, Detroit, Michigan, USA  
**Min-Xin Guan**, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA  
**Maureen R. Hanson**, Cornell University, Ithaca, New York, USA  
**Charles L. Hoppel**, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA  
**Paul M. Hwang**, National Institutes of Health (NIH), Bethesda, Maryland, USA  
**Grazia Isaya**, Mayo Clinic, Rochester, Minnesota, USA  
**Naoaki Ishii**, Tokai University School of Medicine, Kanagawa, Japan  
**Laura S. Kaguni**, Michigan State University, East Lansing, Michigan, USA  
**Konstantin Khrapko**, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA  
**Kiyoshi Kita**, Nagasaki University, Nagasaki, Japan  
**John J. Lemasters**, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA  
**Alfred Lewin**, University of Florida College of Medicine, Gainesville, Florida, USA  
**Jiankang Liu**, Xi'an Jiaotong University, Xi'an, China

**Hideyuki J. Majima**, Kagoshima University Graduate School of Medical & Dental Sciences, Kagoshima, Japan  
**Dan Mishmar**, Ben-Gurion University of the Negev, Beer Sheva, Israel  
**Max Møller**, Aarhus University, Slagels, Denmark  
**Carlos T. Moraes**, University of Miami, Miller School of Medicine, Miami, Florida, USA  
**Arnold Munnich**, Hôpital Necker - Enfants Malades, Paris, France  
**Robert K. Naviaux**, University of California at San Diego (UCSD), San Diego, California, USA  
**Thomas O'Brien**, University of Florida, Gainesville, Gainesville, Florida, USA  
**Shigeo Ohta**, Nippon Medical School, Kawasaki City, Kanagawa, Japan  
**Debkumar Pain**, University Medical & Dental School of New Jersey, Newark, New Jersey, USA  
**Sergio Papa**, Università degli Studi di Bari Aldo Moro, Bari, Italy  
**Peter L. Pedersen**, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA  
**George Perry**, University of Texas at San Antonio, San Antonio, Texas, USA  
**Cal Pinkert**, University of Alabama, Tuscaloosa, Alabama, USA  
**Mark Prescott**, Monash University, Victoria, Australia  
**Lene Juel Rasmussen**, University of Copenhagen, Copenhagen, Denmark  
**Rodrigue Rossignol**, Institute for Health and Medical Research, Bordeaux, France  
**Michael Sack**, National Institutes of Health (NIH), Bethesda, Maryland, USA  
**Russell P. Saneto**, Seattle Children's Hospital Research Institute, Seattle, Washington, USA  
**Hiromi Sasaki**, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA  
**Gerald S. Shadel**, Yale University School of Medicine, New Haven, Connecticut, USA  
**Jan Smeitink**, Radboudumc, Nijmegen, Netherlands  
**Linda L. Spremulli**, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA  
**Daret St. Clair**, University of Kentucky, Lexington, Kentucky, USA  
**Masashi Tanaka**, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan  
**Mark Tarnopolsky**, McMaster University Medical Center, Hamilton, Ontario, Canada  
**Kumarasamy Thangaraj**, Centre for Cellular and Molecular Biology, Hyderabad, India  
**David R. Thorburn**, Murdoch Childrens Research Institute, Parkville, Victoria, Australia  
**Douglas C. Wallace**, University of California at Irvine, Irvine, California, USA  
**Yau-Huei Wei**, National Yang Ming University, Taipei, Taiwan, ROC  
**Lee-Jun Wong**, Baylor College of Medicine, Houston, Texas, USA  
**Michael P. Yaffee**, University of California at San Diego (UCSD), La Jolla, California, USA  
**Massimo Zeviani**, National Neurological Institute "Carlo Besta", Milano, Italy

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### **INTRODUCTION**

*Mitochondrion* is a definitive, high profile, peer-reviewed international research journal. The scope of *Mitochondrion* is broad, reporting on basic science of mitochondria from all organisms and from basic research to pathology and clinical aspects of mitochondrial diseases. The journal welcomes original contributions from investigators working in diverse sub-disciplines such as evolution, biophysics, biochemistry, molecular and cell biology, genetics, pharmacology, toxicology, forensic science, programmed cell death, aging, cancer and clinical features of mitochondrial diseases.

### *Types of paper*

#### **Original Articles**

Peer-reviewed, high-quality, concise research investigations that represent new and significant contributions to science.

#### **Fast Track Articles**

Peer-reviewed, short studies that are refereed rapidly and published generally within 10 weeks. These papers should be a concise complete piece of work of special significance and timeliness and should not exceed 4 printed pages (i.e., 10 pages of double-spaced typescript, including tables and figures up to a total number of 4).

#### **Review Articles**

Reviews of major importance in mitochondrial biology. These articles will be peer-reviewed. Articles may be of any length; however, unusually long articles should be discussed with the editor before submission.

#### **MitoMatters**

Editorial and news of general interest invited by Editorial Office. Profiles and Perspectives: Invited by Editorial Office and written by senior investigators in the field.

#### **The Mito Mew**

Editorial and news of general interest.

#### **Letters to the Editor**

Comments on papers published in the Journal and on other matters of interest to mitochondria researchers. These should be less than 400 words and may include one illustration or table.

#### **Book Reviews**

Invited by the editorial office.

#### **Announcements and Calendar**

Providing notices of forthcoming meetings, courses, and other events relevant to mitochondria researchers.

### *Contact details for submission*

Please submit manuscripts intended for *Mitochondrion* via the journal's online editorial and submission system available at <http://ees.elsevier.com/mitoch>.

Customer support is available 24/7:

Please use our help site at: <http://epsupport.elsevier.com/>. Here you will be able to learn more about EES via interactive tutorials, explore a range of online submission solutions via our knowledgebase, and find answers to frequently asked questions. You will also find our 24/7 support contact details should you need any assistance from one of our customer service representatives.

For questions regarding the reviewing process, please contact the Editor-in-Chief, Dr. Keshav K. Singh at [mitochondriona@roswellpark.org](mailto:mitochondriona@roswellpark.org) or at

Keshav K. Singh, Ph.D Department of Cancer Genetics Roswell Park Cancer Institute Cell and Virus Building, Room 247 Elm and Carlton Streets Buffalo, NY 14263 USA

### **Submission checklist**

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript:*

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files* (where applicable)

*Supplemental files* (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Relevant declarations of interest have been made
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

## **BEFORE YOU BEGIN**

### **Ethics in publishing**

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

### **Policy and ethics**

When conducting scientific research using human tissue and which is intended for publication in Mitochondrion, authors should follow procedures that are in accordance with the ethical standards as formulated in the Helsinki Declaration of 1975 (revised 1983). When conducting experiments on animals, authors should adhere to the local or national requirements for the care and use of laboratory animals.

### **Declaration of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. [More information](#).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was

carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [CrossCheck](#).

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

*Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

*Funding body agreements and policies*

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our [universal access programs](#).
- No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

#### *Creative Commons Attribution (CC BY)*

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

#### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 2400**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

#### *Green open access*

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

#### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

### **Referees**

Please submit, with the manuscript, the names, addresses and telephone, fax and e-mail details (where possible) of five suitable, potential reviewers. If there are compelling reasons for excluding some individuals as potential reviewers, these may be mentioned. However, the ultimate reviewer selection is at the discretion of the Editor-in-Chief.

### **Additional Information**

After final acceptance of an article, only corrections to the title and list of authors as they appear on the accepted article will be permitted, not changes; particularly, no author names may be added to or deleted from the accepted lists.

The Editor-in-Chief is responsible for the professional review of the manuscripts. Receipt of manuscripts by the Editor-in-Chief will be acknowledged.

All materials submitted become the property of *Mitochondrion*. In the case of rejection of a paper, manuscripts will not be returned to authors.

Mitochondrion is the Official Journal of the Mitochondria Research Society. The journal is included as a part of the annual subscription to the society. Information regarding the society can be obtained from The Mitochondria Research Society, P.O. Box 306, Riderwood, MD 21139-0306, USA or visit the society's web site at <http://www.mitoresearch.org>.

## **PREPARATION**

### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

#### *References*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

#### *Formatting requirements*

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

#### *Figures and tables embedded in text*

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

### **Peer review**

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

### **REVISED SUBMISSIONS**

#### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### **Article structure**



### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract should not exceed **100** words.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

### *Abbreviations*

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

#### *Math formulae*

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

#### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

### **Artwork**

#### *Electronic artwork*

##### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files. A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

#### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

### *Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

### **References**

#### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

#### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

#### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

#### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

#### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/mitochondrion>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

#### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

## RESEARCH DATA

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that give them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### *Data in Brief*

You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for *Data in Brief* as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to *Data in Brief* where it will be editorially reviewed and published in the open access data journal, *Data in Brief*. Please note an open access fee is payable for publication in *Data in Brief*. Full details can be found on the [Data in Brief website](#). Please use [this template](#) to write your Data in Brief.

### *AudioSlides*

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. [More information and examples are available](#). Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### *3D molecular models*

You can enrich your online articles by providing 3D molecular models (optional) in PDB, PSE or MOL/MOL2 format, which will be visualized using the interactive viewer embedded within the article. Using the viewer, it will be possible to zoom into the model, rotate and pan the model, and change display settings. Submitted models will also be available for downloading from your online article on ScienceDirect. Each molecular model will have to be uploaded to the online submission system separately, via the '3D molecular models' submission category. [More information](#).

### *3D models*

You can enrich your online articles by providing 3D models (optional) in PLY, OBJ or U3D format, which will be visualized using the interactive viewer next to the article. Each 3D model will have to be zipped and uploaded to the online submission system via the '3D models' submission category. Please be advised that the recommended model size before zipping is maximum 150 MB. Multiple

models can be submitted. Please provide a short informative description for each model by filling in the 'Description' field when uploading a dataset. Note: all datasets will be available for download from the online article on ScienceDirect. If you have concerns about your data being downloadable, please provide a video instead. More information on [OBJ and PLY models](#) or [U3D models](#).

### **Interactive plots**

This journal enables you to show an Interactive Plot with your article by simply submitting a data file. [Full instructions](#).

### **Virtual Microscope**

The journal encourages authors to supplement in-article microscopic images with corresponding high resolution versions for use with the Virtual Microscope viewer. The Virtual Microscope is a web based viewer that enables users to view microscopic images at the highest level of detail and provides features such as zoom and pan. This feature for the first time gives authors the opportunity to share true high resolution microscopic images with their readers. [More information and examples](#). Authors of this journal will receive an invitation e-mail to create microscope images for use with the Virtual Microscope when their manuscript is first reviewed. If you opt to use the feature, please contact [virtualmicroscope@elsevier.com](mailto:virtualmicroscope@elsevier.com) for instructions on how to prepare and upload the required high resolution images.

## **AFTER ACCEPTANCE**

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2014 Elsevier | <http://www.elsevier.com>